(NAPSI)—Chronic obstructive pulmonary disease (COPD) affects approximately 16 million Americans and can make even simple ...

The first one was that several participants did not know the correct inhaler regimen that they were actively prescribed at ...

A new study published in the Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation shows how an innovative phone-based inhaler education program helped Medicare Advantage ...

After Asha Bhosle’s death from chest infection, doctors explain symptoms, warning signs, stages and treatment, especially ...

AI-powered app Aide offers daily support for long-term conditions across Warrington GP surgeries, aiming to cut avoidable appointments and ...

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce ...

New self-administration option offers same clinical benefits as Saphnelo IV infusion MISSISSAUGA, ON, April 13, 2026 /CNW/ – Health Canada has granted a Notice of Compliance (NOC) for ...

Coughing up phlegm feels gross, especially if you’re already dealing with other unpleasant symptoms from a cold or other ...

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU) ...

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of chronic obstructive pulmonary disease treatments with Verona Pharma’s ...

REMOVING BARRIERS TO PSYCHEDELIC DRUGS AS POTENTIAL TREATMENT FOR SERIOUS MENTAL ILLNESS: Today, President Donald J. Trump ...

By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered: Section 1.  Purpose and ...